October 13, 2026 · Phase 2 readout
VRXA Phase 2 readout: a positive outcome, +5.3%
On October 13, 2026, VY7523 — Veraxa Biotech Holding AG (Alzheimer's Disease (AD)) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +5.3% in the window around the event. It had already run -23.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$1.14
1d before
$1.20
Event day
$1.11
1d after
$1.11
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (-0.4% expected); the stock actually moved +5.3%. Model confidence at the time: 45%.
See the full scored track recordPre-catalyst setup
-23.6%
30-day run-up
9197%
30-day volatility
0.7×
volume spike